166 related articles for article (PubMed ID: 38280761)
1. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
Murray TS; Stanley G; Koff JL
Infect Dis Clin North Am; 2024 Mar; 38(1):149-162. PubMed ID: 38280761
[TBL] [Abstract][Full Text] [Related]
2. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
Murray TS; Stanley G; Koff JL
Clin Chest Med; 2022 Dec; 43(4):667-676. PubMed ID: 36344073
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
Conway SP; Brownlee KG; Denton M; Peckham DG
Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
[TBL] [Abstract][Full Text] [Related]
5. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.
Psoter KJ; De Roos AJ; Wakefield J; Mayer JD; Rosenfeld M
BMC Infect Dis; 2017 Jun; 17(1):411. PubMed ID: 28599639
[TBL] [Abstract][Full Text] [Related]
6. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
Waters V; Ratjen F
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology and management of pulmonary infections in cystic fibrosis.
Gibson RL; Burns JL; Ramsey BW
Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
[TBL] [Abstract][Full Text] [Related]
8. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
Lobo LJ; Tulu Z; Aris RM; Noone PG
Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Jahnke N; Waters V
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009249. PubMed ID: 32189337
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009249. PubMed ID: 27415821
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary infections in patients with cystic fibrosis.
Rajan S; Saiman L
Semin Respir Infect; 2002 Mar; 17(1):47-56. PubMed ID: 11891518
[TBL] [Abstract][Full Text] [Related]
13. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.
Waters V
Curr Pharm Des; 2012; 18(5):696-725. PubMed ID: 22229574
[TBL] [Abstract][Full Text] [Related]
14. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2014 Apr; (4):CD009249. PubMed ID: 24696136
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2012 May; (5):CD009249. PubMed ID: 22592739
[TBL] [Abstract][Full Text] [Related]
17. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
Rutter WC; Burgess DR; Burgess DS
Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
19. Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis.
Psoter KJ; De Roos AJ; Wakefield J; Mayer JD; Rosenfeld M
BMC Pulm Med; 2017 Jul; 17(1):106. PubMed ID: 28750627
[TBL] [Abstract][Full Text] [Related]
20.
Caverly LJ; Spilker T; Kalikin LM; Stillwell T; Young C; Huang DB; LiPuma JJ
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
